2018
Progressive T1 Shortening of the Dentate Nucleus in Patients With Multiple Sclerosis: Result of Multiple Administrations of Linear Gadolinium Contrast Agents Versus Intrinsic Disease.
Malhotra A, LeSar B, Wu X, Durand D, Das N, Anzai Y, Sanelli P. Progressive T1 Shortening of the Dentate Nucleus in Patients With Multiple Sclerosis: Result of Multiple Administrations of Linear Gadolinium Contrast Agents Versus Intrinsic Disease. American Journal Of Roentgenology 2018, 211: 1099-1105. PMID: 30160975, DOI: 10.2214/ajr.17.19155.Peer-Reviewed Original ResearchConceptsMacrocyclic agent gadobutrolMultiple sclerosisGlobus pallidusDentate nucleusGadolinium-based contrast agentsGadopentetate dimeglumineIntrinsic diseaseContrast injectionMultiple administrationsRelapsing-remitting multiple sclerosisMultiple contrast injectionsSubsequent MRI studiesUnenhanced T1-weighted imagesT1-weighted imagesIntrinsic T1 hyperintensityPons SI ratioContrast agent administrationRetrospective reviewMore dosesT1 hyperintensitySignal intensity ratioContrast agentsGadolinium contrastMRI studiesPatientsDentate nucleus T1 hyperintensity: is it always gadolinium all that glitters?
Pasquini L, Rossi Espagnet M, Napolitano A, Longo D, Bertaina A, Visconti E, Tomà P. Dentate nucleus T1 hyperintensity: is it always gadolinium all that glitters? La Radiologia Medica 2018, 123: 469-473. PMID: 29374857, DOI: 10.1007/s11547-017-0846-3.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsB-cell acute lymphoblastic leukemiaRadiological findingsLinear gadolinium-based contrast agentsMacrocyclic gadolinium-based contrast agentsPre-contrast T1-weighted imagesNormal renal functionAcute lymphoblastic leukemiaT1-weighted imagesAccurate clinical dataRenal functionHuman post-mortem studiesLymphoblastic leukemiaHyperintense signalB cellsDifferential diagnosisGadolinium accumulationVulnerable brain regionsClinical dataPost-mortem studiesPost-irradiation changesMultiple administrationsDentate nucleusGd depositionMagnetic resonance
2012
Glycolipid Antigens for Treating Hepatic Colorectal Cancer Metastases and Their Effect on the Therapeutic Efficacy of Live Attenuated Listeria monocytogenes
Olino K, Edil BH, Meckel KF, Pan X, Thuluvath A, Pardoll DM, Schulick RD, Yoshimura K, Weber WP. Glycolipid Antigens for Treating Hepatic Colorectal Cancer Metastases and Their Effect on the Therapeutic Efficacy of Live Attenuated Listeria monocytogenes. JAMA Surgery 2012, 147: 480-482. PMID: 22785644, PMCID: PMC4144826, DOI: 10.1001/archsurg.2011.2206.Peer-Reviewed Original ResearchConceptsNatural killer T cellsHepatic colorectal cancer metastasesKiller T cellsColorectal cancer metastasisT cellsNatural Killer T Cell SubsetsCancer metastasisAntitumor activityT cell subsetsAttenuated Listeria monocytogenesPotential of glycolipidsTumor challengeHepatic metastasesMultiple administrationsGlycolipid antigensTherapeutic efficacyListeria monocytogenesActin AAntitumor efficacyMetastasisFurther investigationAdministrationEfficacySpecific glycolipidsSurvival
2006
A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration
Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA, Group C. A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration. Ophthalmology 2006, 113: 1522.e1-1522.e14. PMID: 16876249, DOI: 10.1016/j.ophtha.2006.05.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChoroidal NeovascularizationDose-Response Relationship, DrugFemaleFluorescein AngiographyHumansInfusions, IntravenousMacular DegenerationMaleMaximum Tolerated DoseMiddle AgedReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaTomography, Optical CoherenceVisual AcuityConceptsVascular endothelial growth factor trapAge-related macular degenerationVEGF TrapRetinal thicknessVisual acuityMacular degenerationEarly Treatment Diabetic Retinopathy Study protocolNeovascular age-related macular degenerationDiabetic Retinopathy Study protocolPlacebo-controlled clinical trialDoses 2 weeksDose-limiting toxicityPhase I trialMean percent changeVEGF receptor 1Optical coherence tomographyAdverse eventsI trialDose groupChoroidal neovascularizationStudy protocolClinical trialsStudy populationMultiple administrationsTherapeutic window
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply